A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

This is a phase I/II study. All subjects are patients diagnosed with relapse or refractory (R/R) classic Hodgkin lymphoma (cHL) and has progressed on treatment with PD-1/L1 inhibitor therapy. The purpose of this study is to evaluate the safety and efficacy of AK129 (bispecific antibody targeting LAG-3 and PD-1) monotherapy or in combination with AK117 (anti-CD47 monoclonal antibody) in R/R cHL with PD-1/L1 inhibitor treatment failure.

Trial Details

NCT ID
NCT06642792
Phase
PHASE1 / PHASE2
Sponsor
Akeso
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • AK129
  • AK117
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Age ≥ 18 years old at the time of enrolment.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Expected Survival of ≥ 12 weeks.
  • Diagnosed as R/R cHL according to Lugano 2014 criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →